A six year study looked into drug eluting stents in diabetic patients and the risk of thrombosis….
Almost a thousand patients were enrolled in the study using either everolimus-eluting stents or paclitaxel-eluting stents who underwent PCI. The group receiving a paclitaxel-eluting stent were more likely to have a family history of CAD, insulin-dependent diabetes, a higher number of lesions treated, longer stents used, and a higher proportion of IVUS and glycoprotein IIb/IIIa inhibitors. The everolimus-eluting stent group had more unstable angina at initial diagnosis, and more type C and distal lesions.
Patients with paclitaxel-eluting stents at 30 days had a higher rate of thrombosis and target lesion revascularization-major adverse cardiac events. The patients also had both a higher thrombosis rate at 6 and 12 months and also higher mortality at 12 months compared to the everolimus-eluting stents. The amount of lesion revascularization-major adverse cardiac events was similar in both groups at 12 months. Stent thrombosis occurrence was lower in the paclitaxel-eluting stent group.